1. A randomized, placebo‐controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER). Issue 12 (4th October 2020) Authors: Austin, Cary D.; Gonzalez Edick, Melissa; Ferrando, Ronald E.; Solon, Margaret; Baca, Miriam; Mesh, Kathryn; Bradding, Peter; Gauvreau, Gail M.; Sumino, Kaharu; FitzGerald, J. Mark; Israel, Elliot; Bjermer, Lief; Bourdin, Arnaud; Arron, Joseph R.; Choy, David F.; Olsson, Julie K.; Abreu, Francis;... Journal: Clinical & experimental allergy Issue: Volume 50:Issue 12(2020) Page Start: 1342 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Low immunogenicity of emicizumab in persons with haemophilia A. Issue 6 (4th September 2021) Authors: Schmitt, Christophe; Emrich, Thomas; Chebon, Sammy; Fernandez, Elena; Petry, Claire; Yoneyama, Koichiro; Kiialainen, Anna; Howard, Monet; Niggli, Markus; Paz‐Priel, Ido; Chang, Tiffany Journal: Haemophilia Issue: Volume 27:Issue 6(2021) Page Start: 984 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosis. Issue 2 (4th February 2021) Authors: Maher, Toby M.; Costabel, Ulrich; Glassberg, Marilyn K.; Kondoh, Yasuhiro; Ogura, Takashi; Scholand, Mary Beth; Kardatzke, David; Howard, Monet; Olsson, Julie; Neighbors, Margaret; Belloni, Paula; Swigris, Jeffrey J. Journal: European respiratory journal Issue: Volume 57:Issue 2(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗